Trial Outcomes & Findings for Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors (NCT NCT01100658)

NCT ID: NCT01100658

Last Updated: 2015-03-27

Results Overview

Child performance on neuropsychological testing (i.e., using Test of Variables of Attention \[TOVA\] which is a computerized test of attention that assists in the screening, diagnosis, and treatment monitoring of attention disorders, like Attention Deficit Hyperactivity Disorder \[ADHD\], and working memory index of the WisSC IV. Standard scores average = 100 +/- 15. Higher scores indicate better performance. Scores \< or = 1 SD below the mean represent area of deficit.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

1 participants

Primary outcome timeframe

Week 1 and Week 2

Results posted on

2015-03-27

Participant Flow

Only 1 patient was enrolled in this study. This patient completed baseline assessment, but withdrew from the study before beginning the medication trial. No medications/placebo were administered.

Participant milestones

Participant milestones
Measure
Participant With Attention Deficit
Participant previously had acute lymphoblastic leukemia or brain tumor to be treated with Methylphenidate or Placebo - Administered 1 capsule each day for 1 week, .3 mg/kg dose.
Overall Study
STARTED
1
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Participant With Attention Deficit
Participant previously had acute lymphoblastic leukemia or brain tumor to be treated with Methylphenidate or Placebo - Administered 1 capsule each day for 1 week, .3 mg/kg dose.
Overall Study
Withdrawal by Subject
1

Baseline Characteristics

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Participant With Attention Deficit
n=1 Participants
Participant previously had acute lymphoblastic leukemia or brain tumor to be treated with Methylphenidate or Placebo - Administered 1 capsule each day for 1 week, .3 mg/kg dose.
Age, Categorical
<=18 years
1 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
0 Participants
n=5 Participants
Sex: Female, Male
Male
1 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Week 1 and Week 2

Population: No patients received treatment, therefore analysis was not done.

Child performance on neuropsychological testing (i.e., using Test of Variables of Attention \[TOVA\] which is a computerized test of attention that assists in the screening, diagnosis, and treatment monitoring of attention disorders, like Attention Deficit Hyperactivity Disorder \[ADHD\], and working memory index of the WisSC IV. Standard scores average = 100 +/- 15. Higher scores indicate better performance. Scores \< or = 1 SD below the mean represent area of deficit.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Week 1 and Week 2

Population: No patients received treatment, therefore analysis was not done.

Parent and teacher ratings of attention, executive function and behavior (i.e., Behavior Rating Inventory of Executive Function \[BRIEF -a parent questionnaire and a teacher questionnaire-designed to assess executive functioning in home and school environments. Conners Parent Rating Scale-3 Short Form \[CPRS-3 research and clinical tool for obtaining parental reports of childhood behavior problems.\] Standard scores average = 50 + or - 10. Higher scores indicate more severe difficulty. Scores \> or = 60 represent areas of significant behavior concern.

Outcome measures

Outcome data not reported

Adverse Events

Participant With Attention Deficit

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Alicia Kunin-Batson

Masonic Cancer Center, University of Minnesota

Phone: 612-624-6931

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place